メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
嘉田 晃子
橋渡し研究シーズ探索センター
h-index
1335
被引用数
21
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2003
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(112)
類似のプロファイル
(6)
フィンガープリント
Akiko Kadaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Apoplexy
100%
Subarachnoid Hemorrhage
38%
Pediatrics
34%
Acute Lymphoblastic Leukemia
31%
Hospital Mortality
28%
Disease
27%
Brain Ischemia
26%
Clinical Trial
25%
Randomized Controlled Trial
23%
Pediatrics Patient
23%
Epileptic Seizure
23%
Arm
19%
Adverse Event
18%
Atrial Fibrillation
18%
Dexamethasone
17%
B Cell
17%
Retrospective Cohort Study
16%
Surgery
16%
Chronic Myelogenous Leukemia
15%
Anaplastic Large Cell Lymphoma
15%
High Risk Population
15%
Phase II Trials
15%
Rituximab
15%
Brain Tumor
15%
Tyrosine-Kinase Inhibitor
15%
Hodgkin's Lymphoma
15%
Pneumothorax
15%
Pleurodesis
15%
Brain Cancer
15%
Rapamycin
15%
Tongue Depressor
15%
Gemcitabine
15%
Cortical Dysplasia
15%
Health Care Cost
15%
Triage
15%
Event Free Survival
14%
Overall Survival
14%
Heart Function
13%
Artificial Respiration
13%
Prognostic Factor
13%
Survival Rate
13%
Cisplatin
13%
Clinical Study
12%
Heart Failure
12%
Radiation Therapy
12%
Cerebral Hemorrhage
12%
Oropharynx
11%
Pharynx
11%
Diffuse Large B-Cell Lymphoma
11%
Cardiovascular System
11%
Pharmacology, Toxicology and Pharmaceutical Science
Dexamethasone
49%
Anaplastic Large Cell Lymphoma
39%
Phase II Trials
34%
Non Small Cell Lung Cancer
31%
Epidermal Growth Factor Receptor
31%
Clinical Trial
24%
Adverse Event
24%
Bortezomib
23%
Randomized Controlled Trial
23%
Warfarin
23%
Brain Ischemia
23%
Paclitaxel
21%
Anaplastic Lymphoma Kinase
21%
Hospital Mortality
21%
Overall Survival
19%
Disease
18%
Carboplatin
17%
Docetaxel
17%
Gemcitabine
16%
Vasospasm
15%
Seizure
15%
Cortical Dysplasia
15%
Acute Lymphoblastic Leukemia
15%
Brentuximab Vedotin
15%
Hodgkin Disease
15%
Rapamycin
15%
Bevacizumab
15%
Idiopathic Thrombocytopenic Purpura
15%
Brain Hemorrhage
15%
Syndrome
15%
Acute Heart Failure
15%
Alectinib
15%
Gefitinib
15%
Multiple Myeloma
15%
Subarachnoid Hemorrhage
15%
Direct Oral Anticoagulant
15%
Osimertinib
15%
Comorbidity
15%
Heart Failure
14%
Ozagrel
13%
Fasudil
13%
Cisplatin
13%
Cohort Study
12%
Progression Free Survival
12%
Chemotherapy
12%
Prospective Cohort Study
12%
Lenalidomide
11%
Brain Natriuretic Peptide
10%
Cardiovascular Disease
10%
Combination Therapy
9%
Keyphrases
Anaplastic Large Cell Lymphoma
31%
Relapsed or Refractory
31%
Japan
28%
Phase II Trial
26%
Comprehensive Stroke Center
23%
Comprehensive Stroke Care
15%
High-dose Dexamethasone Therapy
15%
Alectinib
15%
SGN-35
15%
CD30 Positive
15%
Anaplastic Lymphoma Kinase-positive
15%
Ischemic Stroke
15%
In-hospital Mortality
15%
Adverse Events
12%
Progression-free Survival
9%
Patient Outcomes
8%
Acute Stroke Care
8%
Response Rate
8%
Prehospital Time
7%
Tyrosine Kinase Inhibitor Discontinuation
7%
EDNRB
7%
Acute Myocardial Infarction
7%
Focal Cortical Dysplasia
7%
Brentuximab Vedotin
7%
ALK-positive Large B-cell Lymphoma
7%
Aneurysmal Subarachnoid Hemorrhage (aSAH)
7%
Bortezomib
7%
Over 75
7%
Sex Differences
7%
Reading Difficulties
7%
Bicaval Anastomosis
7%
Japanese children
7%
Treatment Modalities
7%
Transplant Eligibility
7%
Public Awareness
7%
Mimickers
7%
Cyclooxygenase-1 (COX-1)
7%
Refractory Neuroblastoma
7%
PTK2B
7%
Atrial Fibrillation
7%
Karen
7%
Malin
7%
Highlands
7%
Bevacizumab
7%
Mature B-cell non-Hodgkin Lymphoma
7%
Tissue Removal
7%
Neurosurgical Research
7%
Medical Diagnostic Test
7%
Polygon-based Method
7%
Thrombotic Thrombocytopenic Purpura
7%
